{"filing":{"accession_number":"0001213900-26-080267","cik":"0001897532","ticker":"PASW","company_name":"Ping An Biomedical Co., Ltd.","form":"6-K","filing_date":"2026-07-22","report_date":null,"primary_document":"ea0298847-6k_pingan.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1897532/000121390026080267/ea0298847-6k_pingan.htm"},"events":[{"id":19412,"run_id":17469,"accession_number":"0001213900-26-080267","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces a strategic cooperation agreement between Ping An Biomedical and Yuan Sheng Mei Yan targeting RMB 500 million in cumulative sales over three years. The agreement establishes a channel development partnership combining Ping An's biotechnology products with Yuan Sheng Mei Yan's health services and distribution capabilities. While this is a material commercial partnership that could significantly impact revenue and market expansion, it does not fit the specific event categories (M\u0026A, debt, equity issuance, etc.) and is best classified as an operational/strategic business event.","company_name":"Ping An Biomedical Co., Ltd.","ticker":"PASW","filing_date":"2026-07-22","form":"6-K","submitted_at":null,"items":[{"id":18495,"accession_number":"0001213900-26-080267","item_number":"EX-99.1","item_title":"ea029884701ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces a strategic cooperation agreement between Ping An Biomedical and Yuan Sheng Mei Yan targeting RMB 500 million in cumulative sales over three years. The agreement establishes a channel development partnership combining Ping An's biotechnology products with Yuan Sheng Mei Yan's health services and distribution capabilities. While this is a material commercial partnership that could significantly impact revenue and market expansion, it does not fit the specific event categories (M\u0026A, debt, equity issuance, etc.) and is best classified as an operational/strategic business event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T15:17:41.191623+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18495,"accession_number":"0001213900-26-080267","item_number":"EX-99.1","item_title":"ea029884701ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces a strategic cooperation agreement between Ping An Biomedical and Yuan Sheng Mei Yan targeting RMB 500 million in cumulative sales over three years. The agreement establishes a channel development partnership combining Ping An's biotechnology products with Yuan Sheng Mei Yan's health services and distribution capabilities. While this is a material commercial partnership that could significantly impact revenue and market expansion, it does not fit the specific event categories (M\u0026A, debt, equity issuance, etc.) and is best classified as an operational/strategic business event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T15:17:41.191623+00:00","company_name":"Ping An Biomedical Co., Ltd.","ticker":"PASW","filing_date":"2026-07-22"}]}